Open-label, One-arm, Multi-centre Phase II Clinical Trial Treated With Second Cycle of Active Cellular Immunotherapy With DCVAC/PCa in Patients With Localized Prostate Cancer After Primary Radical Prostatectomy Without Objective Progression [EXTENSION OF 700214990]
Phase of Trial: Phase II
Latest Information Update: 30 May 2017
Price : $35 *
At a glance
- Drugs Stapuldencel-T (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors SOTIO
- 31 Aug 2018 Biomarkers information updated
- 20 May 2017 Status changed from active, no longer recruiting to completed.
- 30 Jun 2015 Planned End Date changed from 1 Mar 2018 to 1 Apr 2017 as per ClinicalTrial.gov record.